Tempus Wealth Planning LLC Reduces Stock Position in Johnson & Johnson $JNJ

Tempus Wealth Planning LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, Holdings Channel.com reports. The fund owned 8,984 shares of the company’s stock after selling 168 shares during the quarter. Tempus Wealth Planning LLC’s holdings in Johnson & Johnson were worth $1,372,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Elios Financial Group Inc. increased its position in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after purchasing an additional 66 shares during the period. Atlantic Family Wealth LLC grew its holdings in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after acquiring an additional 67 shares during the period. MBA Advisors LLC grew its holdings in shares of Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. lifted its stake in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its position in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after purchasing an additional 69 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on JNJ shares. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Citigroup lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Finally, The Goldman Sachs Group raised their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Price Performance

NYSE JNJ opened at $179.69 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The stock has a 50-day moving average of $174.41 and a 200 day moving average of $162.05. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $432.75 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm posted $2.82 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.